Despite decades of research and countless treatment programs, the question of “What Causes Addiction, and Why Is It So Hard ...

New study reveals gum disease treatment can reduce cardiovascular risk by 10% annually, with intensive dental cleanings showing significant heart health benefits.

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic ...